Warning: mysqli_query(): (HY000/1): Can't create/write to file '/tmp/#sql_4f7_1.MYI' (Errcode: 28 - No space left on device) in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
Cyclacel Pharmaceuticals, Inc. (CYCC) Analysts See $-0.11 EPS - Money Making Articles Hot Stuff

Cyclacel Pharmaceuticals, Inc. (CYCC) Analysts See $-0.11 EPS

October 14, 2018 - By Adrian Mccoy

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) LogoInvestors sentiment decreased to 0 in 2018 Q2. Its down Infinity, from Infinity in 2018Q1. It turned negative, as 0 investors sold Cyclacel Pharmaceuticals, Inc. shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 29,468 shares or 122.35% more from 13,253 shares in 2018Q1 were reported.
Baker Bros Advsr Ltd Partnership reported 13,253 shares. Citigroup holds 0% or 1,481 shares.

Analysts expect Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) to report $-0.11 EPS on November, 8.They anticipate $0.80 EPS change or 87.91 % from last quarter’s $-0.91 EPS. After having $-0.16 EPS previously, Cyclacel Pharmaceuticals, Inc.’s analysts see -31.25 % EPS growth. The stock increased 2.22% or $0.03 during the last trading session, reaching $1.38. About 30,057 shares traded. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has declined 27.66% since October 14, 2017 and is downtrending. It has underperformed by 43.28% the S&P500.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Ratings Coverage

Among 2 analysts covering Cyclacel Pharmaceuticals (NASDAQ:CYCC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cyclacel Pharmaceuticals had 2 analyst reports since May 15, 2018 according to SRatingsIntel. As per Tuesday, May 15, the company rating was maintained by H.C. Wainwright.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company has market cap of $16.56 million. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. It currently has negative earnings. The Company’s oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors.

Another recent and important Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) news was published by Globenewswire.com which published an article titled: “Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference” on September 26, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924